A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The study will try to answer these questions:
1. What is the highest dose of thalidomide brain cancer patients can receive safely in
combination with irinotecan?
2. How well does this combination work to shrink brain tumors, and how long do responses to
treatment last?
3. What side effects does the combination of drugs cause?
4. How does treatment affect patients' quality of life (how they feel and what activities
they are able to do)?